We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+19.79%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$121M
Cap. Flow
+$99.3M
Cap. Flow %
27.73%
Top 10 Hldgs %
55.61%
Holding
85
New
30
Increased
11
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$13.4M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.5M
3
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.12M
4
SWTX
SpringWorks Therapeutics
SWTX
+$5.02M
5
AZN icon
AstraZeneca
AZN
+$4.12M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$7.61M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.98M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.69M
4
RPTX
Repare Therapeutics
RPTX
+$4.49M
5
KURA icon
Kura Oncology
KURA
+$3.89M

Sector Composition

Rank Sector Weight
1 Healthcare 51.05%
2 Financials 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
$3.62M 1.01%
+400,043
New +$2.68M
VRNA
27
DELISTED
Verona Pharma
VRNA
$3.58M 1%
+350,000
New +$2.95M
ARYE
28
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$3.46M 0.97%
352,500
– –
GSK icon
29
PUT
GSK
GSK
$101B
$3.24M 0.9%
+110,000
New +$4.17M
CYTK icon
30
Cytokinetics
CYTK
$10.9B
$3.15M 0.88%
65,000
+50,000
+333% +$2.41M
COGT icon
31
Cogent Biosciences
COGT
$6.62B
$2.3M 0.64%
154,087
+29,087
+23% +$399K
CLDX icon
32
Celldex Therapeutics
CLDX
$2.79B
$2.25M 0.63%
80,000
+40,000
+100% +$1.23M
GSK icon
33
GSK
GSK
$101B
$2.21M 0.62%
+75,000
New +$2.84M
ACRS icon
34
Aclaris Therapeutics
ACRS
$789M
$2.15M 0.6%
136,434
+36,434
+36% +$574K
LNTH icon
35
PUT
Lantheus
LNTH
$6.95B
$2.11M 0.59%
30,000
-40,000
-57% -$3.03M
VINC
36
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.06M 0.58%
74,639
+5,934
+9% +$171K
FXE icon
37
PUT
Invesco CurrencyShares Euro Currency Trust
FXE
$332M
$1.81M 0.5%
+20,000
New +$1.86M
VRNA
38
PUT
DELISTED
Verona Pharma
VRNA
$1.69M 0.47%
+165,100
New +$1.39M
GERN icon
39
PUT
Geron
GERN
$917M
$1.52M 0.42%
+650,000
New +$1.46M
RXDX
40
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$1.48M 0.41%
+25,000
New +$1.14M
GERN icon
41
CALL
Geron
GERN
$917M
$1.47M 0.41%
+626,000
New +$1.4M
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$1.4M 0.39%
+96,318
New +$1.35M
MIST icon
43
CALL
Milestone Pharmaceuticals
MIST
$147M
$1.26M 0.35%
+137,200
New +$1.04M
LIAN
44
DELISTED
LianBio American Depositary Shares
LIAN
$1.09M 0.31%
550,000
+100,000
+22% +$239K
FXB icon
45
PUT
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.4M
$1.07M 0.3%
+10,000
New +$1.13M
CNTX icon
46
Context Therapeutics
CNTX
$56M
$981K 0.27%
883,654
– –
CNTA
47
DELISTED
Centessa Pharmaceuticals
CNTA
$975K 0.27%
+242,517
New +$1.11M
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$792K 0.22%
+110,000
New +$907K
NAUT icon
49
Nautilus Biotechnolgy
NAUT
$217M
$790K 0.22%
372,476
-94,131
-20% -$237K
VERV
50
CALL
DELISTED
Verve Therapeutics
VERV
$687K 0.19%
+20,000
New +$638K
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Affinity Asset Advisors held 85 positions worth $358M, up 51% from $237M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Affinity Asset Advisors deployed $99.3M of net new capital in Q3 2022, opening 30 new positions and adding to 11 existing holdings. Its largest new stake was Sanofi: 300,000 shares worth $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 64% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $7.61M trimmed.

  • Affinity Asset Advisors's largest Q3 2022 buy was Sanofi: 300,000 shares worth $11.4M.
  • Affinity Asset Advisors added most to POINT Biopharma Global Inc. Common Stock in Q3 2022, an estimated $6.12M increase.
  • Affinity Asset Advisors's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $7.61M.
  • Affinity Asset Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $5.98M.
  • Affinity Asset Advisors's ten largest holdings make up 56% of its $358M portfolio in Q3 2022.
  • Affinity Asset Advisors opened 30 new positions and closed 21 in Q3 2022.
  • Affinity Asset Advisors's portfolio value rose 51% quarter-over-quarter to $358M.

Based on Affinity Asset Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.